Zum Artikel

Dr. Angelika Vlachou Partner

Dr. Angelika VlachouPartner

About me

Team Berlin Team, Investment comittee, Life Sciences & Chemistry, Partner
at HTGF since 2021

CV

Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.

Social Media
& contact

My success stories
in the HTGF portfolio

6 of 500 Companies
2024

SRTD biotech

North Rhine-Westphalia
Oncology

SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …

To the complete profileof SRTD biotech
2022

smartbax

Life Sciences

smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address …

To the complete profileof smartbax
2022

Kupando

Brandenburg

Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to …

To the complete profileof Kupando
2022

faCellitate

Baden-Württemberg
R&D Tools

faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …

To the complete profileof faCellitate
2019

Lindis Blood Care

Berlin
Patient Monitoring

Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …

To the complete profileof Lindis Blood Care
2019

mediaire

Berlin
Imaging & Navigation

mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …

To the complete profileof mediaire
2018

miRdetect

Bremen
In-Vitro Dx

miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …

To the complete profileof miRdetect

Guided
to exit

6 of 500 Companies
2018

adivo

Bavaria
Exit
Agriculture, Agritech & Animal Health

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species. Antibody …

To the complete profileof adivo

Recent
posts

Last update 12 hours ago
Zum Artikel

News

28. February 2025

Successful exit for HTGF: Pacira BioSciences Acquires GQ Bio

Zum Artikel

Story

27. February 2025

Innovation, Investments, Impact: A Look Back at HTGF’s Biotech Year 2024

Zum Artikel

News

13. December 2024

Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB®

Zum Artikel

News

14. November 2024

SRTD biotech secures seed financing: Side-effect freeRNA therapeutics active only in diseased cells

Zum Artikel

News

13. November 2024

mediaire transforms radiology with AI, securing a European €12 million investment to fuel global growth

Zum Artikel

Story

18. January 2024

Zum Artikel

News

15. September 2023

Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide

Zum Artikel

News

23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

Zum Artikel

News

29. September 2022

Dr. Angelika Vlachou and Stefanie Grüter appointed partners at High-Tech Gründerfonds

KUPANDO Logo Zum Artikel

Press

26. September 2022

Kupando raises €13 million in Series A funding round

Zum Artikel

News

7. September 2022

faCellitate, a BASF spin-off, closes a €3.7m seed round led by SARSTEDT and HTGF

Zum Artikel

News

9. February 2022

Lindis Blood Care successfully closes follow-on financing round